Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Fiche publication
Date publication
mai 2017
Journal
Journal of the National Cancer Institute
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouché O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Francois Emile J, Laurent Puig P, Sinicrope FA
Lien Pubmed
Résumé
The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/- cetuximab in two adjuvant therapy trials.
Mots clés
Adenocarcinoma, genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cetuximab, administration & dosage, Chemotherapy, Adjuvant, Colectomy, Colonic Neoplasms, genetics, DNA Mismatch Repair, Female, Fluorouracil, therapeutic use, Humans, Leucovorin, therapeutic use, Male, Microsatellite Instability, Middle Aged, Mutation, Neoplasm Recurrence, Local, genetics, Neoplasm Staging, Organoplatinum Compounds, therapeutic use, Prognosis, Proto-Oncogene Proteins B-raf, genetics, Proto-Oncogene Proteins p21(ras), genetics, Survival Rate, Time Factors, Young Adult
Référence
J. Natl. Cancer Inst.. 2017 May;109(5):